(NASDAQ: TRAW) Traws Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.74%.
Traws Pharma's revenue in 2024 is $226,000.On average, 1 Wall Street analysts forecast TRAW's revenue for 2024 to be $139,155,550, with the lowest TRAW revenue forecast at $139,155,550, and the highest TRAW revenue forecast at $139,155,550. On average, 1 Wall Street analysts forecast TRAW's revenue for 2025 to be $7,590,303, with the lowest TRAW revenue forecast at $7,590,303, and the highest TRAW revenue forecast at $7,590,303.
In 2026, TRAW is forecast to generate $7,590,303 in revenue, with the lowest revenue forecast at $7,590,303 and the highest revenue forecast at $7,590,303.